● AI Equity Research · Healthcare

Boston Scientific Corporation (BSX)

AI stock analysis · Medical Devices · Last analyzed Aug 17, 2026

Compass Score

3.0/5

Call

Hold

Price

$51.83

AI Target

$62.69 +21.0%

AI Analyst Summary

Boston Scientific presents a compelling growth-at-a-reasonable-price opportunity, underpinned by a PEG ratio of 0.74 and a forward P/E of 15.1x — attractive for a best-in-class MedTech franchise posting 15.1% earnings growth and 7.5% revenue expansion. The company's diversified device portfolio, spanning electrophysiology, endoscopy, and cardiovascular intervention, provides multiple durable growth vectors with consistent execution evidenced by four straight EPS beats. The primary risk is macroeconomic and procedural volume sensitivity, as healthcare spending headwinds or hospital capacity constraints could pressure near-term revenue growth.

Catalysts

Continued commercial ramp of the FARAPULSE pulsed field ablation system in electrophysiology, a fast-growing market segment that could meaningfully expand BSX's share in cardiac rhythm management over the next 2–4 quarters.
Upcoming quarterly earnings report expected to demonstrate continued double-digit EPS growth and potential upward revision to full-year guidance, reinforcing the forward P/E compression thesis.
Expansion of the endoscopy and urology product lines into international markets, particularly in Asia-Pacific, where procedural volume growth rates are outpacing developed markets.

Fundamentals

Pe Trailing P/E 21.0x / Forward P/E 15.1x · 4.0/5

Trailing P/E of 21.0x is reasonable for a high-quality medical device company, and the forward P/E of 15.1x suggests meaningful earnings expansion ahead. Valuation is below many large-cap MedTech peers on a forward basis, making it constructively priced relative to growth.

Peg PEG Ratio: 0.74 · 5.0/5

PEG of 0.74 is well below 1.0, indicating the market is not fully pricing in the company's durable earnings growth. This is a strong signal that the stock is undervalued relative to its growth trajectory.

Analyst Rating Strong Buy consensus (1.6) · 4.0/5

Consensus of 1.6 on an inverted scale reflects overwhelmingly bullish sentiment, with 26 Buy ratings, 5 Holds, and 0 Sells across 29 analysts. This maps to a score of 4, reflecting broad conviction with only a small minority neutral.

Earnings Trend EPS Growth YoY: +15.1% | Revenue Growth YoY: +7.5% · 4.0/5

15.1% YoY earnings growth is well above the broader healthcare sector median and supported by solid 7.5% revenue growth, signaling operational leverage. Growth is healthy but not yet in the accelerating >25% tier to warrant a 5.

Price Target Beat EPS Beat Rate: 4 of 4 quarters · 4.0/5

A perfect 4-for-4 beat rate over the last four quarters demonstrates consistent execution. Only 4 quarters of data are available, so a score of 5 (requiring 6 of 8 beats) is not applicable, but the trend is highly encouraging.

Management Consistent execution with strong analyst confidence · 4.0/5

A flawless recent EPS beat record, paired with near-unanimous bullish analyst sentiment and no Sell ratings among 29 analysts, reflects strong management credibility. Capital allocation and operational delivery appear well-regarded by the investment community.

● See the full picture

Get today's top-scored picks, ranked for you.

Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.

Start free for 3 days →

No credit card. Then $9/month. Cancel anytime.

How Compass scores stocks

Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →

Not financial advice. Compass is an analytical tool, not a registered investment adviser or broker-dealer. Scores and recommendations are generated by AI, may be inaccurate or out of date, and are not investment, financial, legal, or tax advice. Investing involves risk, including loss of principal. Do your own research and consult a licensed financial professional. About Compass.